Randomized, Double Blinded, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease
I. Rosas (Houston, United States), J. Solomon (Denver, United States), S. Donoff (Baltimore, United States), F. Woodhead (Leicester, United Kingdom), G. Raghu (Seattle, United States), G. Hilary (Boston, United States), T. Network Investigators (NETWORK, United States)
Source: International Congress 2022 – ALERT 3: COVID and interstitial lung diseases??
Session: ALERT 3: COVID and interstitial lung diseases??
Session type: Clinical trials session
Number: 2886
  
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
I. Rosas (Houston, United States), J. Solomon (Denver, United States), S. Donoff (Baltimore, United States), F. Woodhead (Leicester, United Kingdom), G. Raghu (Seattle, United States), G. Hilary (Boston, United States), T. Network Investigators (NETWORK, United States). Randomized, Double Blinded, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease. 2886
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|